The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Rheumatology in the Age of COVID-19: HCQ Shortages Driven by Small, Nonrandomized Study

Rheumatology in the Age of COVID-19: HCQ Shortages Driven by Small, Nonrandomized Study

March 28, 2020 • By Michael Putman, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

On March 17, Gautret et al. published a manuscript reporting beneficial effects from hydroxychloroquine in COVID-19 in the International Journal of Antimicrobial Agents.1 At a presidential press conference three days later, President Trump discussed hydroxychloroquine, asserting, “It’s shown very encouraging—very, very encouraging early results.” Shortly thereafter, pharmacies around the world reported shortages. Kaiser Permanente went so far as to restrict access to hydroxychloroquine, including for many patients with rheumatic conditions. Rheumatologists everywhere have been left wondering what happened and how to move forward.

You Might Also Like
  • HCQ Prolongs QT Interval in Patients with COVID-19
  • U.S. FDA Says HCQ & Other Malaria Drugs in Shortage as COVID-19 Drives Up Demand
  • FDA Accelerates Approvals of Generic Versions of HCQ
Explore This Issue
May 2020
Also By This Author
  • FDA Approves Nintedanib for SSc-ILD, But Temper Your Expectations

At first glance, the enthusiasm for hydroxychloroquine had merit. Multiple in vitro studies have demonstrated encouraging results, and unpublished reports from China suggested a clinical benefit.2,3 Hydroxychloroquine has an acceptable safety profile and a reasonable cost. An editorial in mid-February by Didier Raoult, also the senior author of the Gautret paper, made the audacious claim, “If clinical data confirm the biological results, the novel coronavirus-associated disease will have become one of the simplest and cheapest to treat and prevent among infectious respiratory diseases.”4

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Clinical data arrived just four weeks later, when Gautret et al. published their experience treating COVID-19 with hydroxychloroquine in the south of France. The manuscript evaluated 42 patients with PCR-confirmed COVID-19 and reported virological cure in 14 of 20 patients (70%) treated with six days of hydroxychloroquine. Only two of the 14 patients in the control group had a virological cure six days after enrollment. All six patients who also received off-protocol azithromycin cleared the virus. Although small, the results appeared to confirm biological data. A closer read of the manuscript, however, suggests otherwise.

Typical of preliminary data, the trial was small, open-label and non-randomized. Studies of this nature suffer from bias and confounding, and frequently do not translate into successful phase 2 or 3 trials. Whether this study is a “trial,” however, should also be questioned. Although the treatment group was recruited from a single center, the control group was recruited separately from various hospitals in the region. Even more troubling, patients who refused or could not tolerate hydroxychloroquine were included in the control group. This design more closely resembles an unnecessarily biased case-control study than a clinical trial. Its results should have been presented and interpreted as such.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Methodological flaws after recruitment compound problems with interpretation of their data. The primary outcome measure, viral clearance at six days, has not been validated and does not necessarily correlate with outcomes that are clinically relevant, such as mortality. Testing of the control group was less rigorous than testing of the treatment group, and almost half of the control group required imputation of their virus results. Most importantly, six of 26 (23%) patients in the treatment group were lost to follow-up and excluded from subsequent analysis. These included patients with the most relevant clinical outcomes, including adverse events (one patient), ICU transfer (three patients) and death (one patient).

Pages: 1 2 3 | Single Page

Filed Under: Conditions, Drug Updates, Opinion Tagged With: COVID-19, HCQ, HYDROXYCHLOROQUINEIssue: May 2020

You Might Also Like:
  • HCQ Prolongs QT Interval in Patients with COVID-19
  • U.S. FDA Says HCQ & Other Malaria Drugs in Shortage as COVID-19 Drives Up Demand
  • FDA Accelerates Approvals of Generic Versions of HCQ
  • Tocilizumab Begins Clinical Trial for COVID-19

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.